ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ETON vs INVA // EV/EBITDA & P/E VALUATION

Eton Pharmaceuticals Inc. (NASDAQ) VS. Innoviva Inc. (NASDAQ) • 15-METRIC TALLY: ETON 2 — INVA 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ETON VS. INVA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ETON INVA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 53.50% 74.80% -21.30 INVA /gross-margins <GO>
Return on Invested Capital (ROIC) -0.90% 14.70% -15.60 INVA /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 7.6x — TIE /valuation <GO>
Free Cash Flow Yield 0.66% 12.72% -12.06 INVA /fcf-yield <GO>
Operating Margin -1.10% 39.80% -40.90 INVA /operating-margins <GO>
Net Profit Margin -5.80% — — TIE /net-margins <GO>
Revenue Growth (YoY) 104.90% 14.70% +90.20 ETON /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 13.37 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 6/9 +1.00 ETON /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.9 53.4 -5.51 INVA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.53B $1.54B -$5.5M INVA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ETON REV INVA REV ETON GROSS % INVA GROSS % ETON FCF INVA FCF
FY 2025 $80.0M $411.3M 53.5% 74.8% $10.2M $195.8M
FY 2024 $39.0M $358.7M 60.0% 82.6% $943.0K $188.4M
FY 2023 $31.6M $310.5M — — $6.8M $141.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ETON // BETA —
INVA // BETA —